Mary E Norton

List of Publications by Year
in descending order

79 papers	3,996 citations	218381 26 h-index	123241 61 g-index
79 all docs	79 docs citations	79 times ranked	3430 citing authors

#	Article	IF	Citations
1	Cell-free DNA Analysis for Noninvasive Examination of Trisomy. New England Journal of Medicine, 2015, 372, 1589-1597.	13.9	639
2	Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. American Journal of Obstetrics and Gynecology, 2012, 207, 137.e1-137.e8.	0.7	453
3	Expanded Carrier Screening in Reproductive Medicineâ€"Points to Consider. Obstetrics and Gynecology, 2015, 125, 653-662.	1.2	305
4	Chorionic Villus Sampling Compared With Amniocentesis and the Difference in the Rate of Pregnancy Loss. Obstetrics and Gynecology, 2006, 108, 612-616.	1.2	215
5	Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #7: nonimmune hydrops fetalis. American Journal of Obstetrics and Gynecology, 2015, 212, 127-139.	0.7	199
6	Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenatal Diagnosis, 2013, 33, 622-629.	1.1	181
7	Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenatal Diagnosis, 2013, 33, 542-546.	1.1	151
8	Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: The fetus at risk for anemiaâ€"diagnosis and management. American Journal of Obstetrics and Gynecology, 2015, 212, 697-710.	0.7	135
9	The use of chromosomal microarray forÂprenatalÂdiagnosis. American Journal of Obstetrics and Gynecology, 2016, 215, B2-B9.	0.7	131
10	Exome Sequencing for Prenatal Diagnosis in Nonimmune Hydrops Fetalis. New England Journal of Medicine, 2020, 383, 1746-1756.	13.9	114
11	Effect of Enhanced Information, Values Clarification, and Removal of Financial Barriers on Use of Prenatal Genetic Testing. JAMA - Journal of the American Medical Association, 2014, 312, 1210.	3.8	105
12	Socioeconomic Mediators of Racial and Ethnic Disparities in Congenital Heart Disease Outcomes: A Populationâ€Based Study in California. Journal of the American Heart Association, 2018, 7, e010342.	1.6	101
13	Chromosome Abnormalities Detected by Current Prenatal Screening and Noninvasive Prenatal Testing. Obstetrics and Gynecology, 2014, 124, 979-986.	1.2	92
14	Mild fetal ventriculomegaly: diagnosis, evaluation, and management. American Journal of Obstetrics and Gynecology, 2018, 219, B2-B9.	0.7	91
15	Risk of selected structural abnormalities in infants after increased nuchal translucency measurement. American Journal of Obstetrics and Gynecology, 2014, 211, 675.e1-675.e19.	0.7	86
16	The role of ultrasound in women who undergo cell-free DNA screening. American Journal of Obstetrics and Gynecology, 2017, 216, B2-B7.	0.7	73
17	Fetal blood sampling. American Journal of Obstetrics and Gynecology, 2013, 209, 170-180.	0.7	70
18	Cell-free DNA vs sequential screening for the detection of fetal chromosomal abnormalities. American Journal of Obstetrics and Gynecology, 2016, 214, 727.e1-727.e6.	0.7	62

#	Article	IF	Citations
19	Gestational dating by metabolic profile at birth: a California cohortÂstudy. American Journal of Obstetrics and Gynecology, 2016, 214, 511.e1-511.e13.	0.7	54
20	Prenatal Testing in the Genomic Age. Obstetrics and Gynecology, 2015, 126, 737-746.	1.2	46
21	Detection Rates for Aneuploidy by First-Trimester and Sequential Screening. Obstetrics and Gynecology, 2015, 126, 753-759.	1.2	43
22	Nonimmune hydrops fetalis: identifying the underlying genetic etiology. Genetics in Medicine, 2019, 21, 1339-1344.	1.1	43
23	Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome. American Journal of Obstetrics and Gynecology, 2022, 227, 79.e1-79.e11.	0.7	35
24	A systemâ€based approach to the genetic etiologies of nonâ€immune hydrops fetalis. Prenatal Diagnosis, 2019, 39, 732-750.	1.1	34
25	Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation. American Journal of Obstetrics and Gynecology, 2022, 227, 259.e1-259.e14.	0.7	30
26	Risk of critical congenital heart defects by nuchal translucency norms. American Journal of Obstetrics and Gynecology, 2015, 212, 518.e1-518.e10.	0.7	28
27	Prenatal Testing Guidelines:. Gynecologic and Obstetric Investigation, 2005, 60, 6-10.	0.7	26
28	Obstetric, Perinatal, and Fetal Outcomes in Pregnancies With False-Positive Integrated Screening Results. Obstetrics and Gynecology, 2014, 123, 603-609.	1.2	24
29	Changing indications for invasive testing in an era of improved screening. Seminars in Perinatology, 2016, 40, 56-66.	1.1	24
30	What are the goals of prenatal genetic testing?. Seminars in Perinatology, 2018, 42, 270-274.	1.1	23
31	Laboratory screening and diagnosis of open neural tube defects, 2019 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2020, 22, 462-474.	1.1	23
32	Cell-Free DNA Screening for Aneuploidy and Microdeletion Syndromes. Obstetrics and Gynecology Clinics of North America, 2018, 45, 13-26.	0.7	21
33	Preferences regarding contemporary prenatal genetic tests among women desiring testing: implications for optimal testing strategies. Prenatal Diagnosis, 2016, 36, 469-475.	1.1	20
34	Diagnostic testing after positive results on cell free DNA screening: CVS or Amnio?. Prenatal Diagnosis, 2021, 41, 1249-1254.	1.1	18
35	2: Cell free DNA analysis vs sequential screening as primary testing considering all fetal chromosomal abnormalities. American Journal of Obstetrics and Gynecology, 2015, 212, S2.	0.7	15
36	Etiology and management of early pregnancy renal anhydramnios: Is there a place for serial amnioinfusions?. Prenatal Diagnosis, 2020, 40, 528-537.	1.1	15

#	Article	IF	Citations
37	Society for Maternal-Fetal Medicine Special Statement: Grading of Recommendations Assessment, Development, and Evaluation (GRADE) update. American Journal of Obstetrics and Gynecology, 2021, 224, B24-B28.	0.7	15
38	Risk of pregnancy loss before 20 weeksâ€™ gestation in study participants with COVID-19. American Journal of Obstetrics and Gynecology, 2021, 225, 456-457.	0.7	14
39	Exome sequencing vs targeted gene panels for the evaluation of nonimmune hydrops fetalis. American Journal of Obstetrics and Gynecology, 2022, 226, 128.e1-128.e11.	0.7	14
40	Maternal Serum CA 125 for aneuploidy detection in early pregnancy. Prenatal Diagnosis, 1992, 12, 779-781.	1.1	12
41	Noninvasive prenatal testing to analyze the fetal genome. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14173-14175.	3.3	12
42	Obstetric care in women with genetic disorders. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 42, 86-99.	1.4	11
43	Utility of chromosomal microarray for diagnosis in cases of nonimmune hydrops fetalis. Prenatal Diagnosis, 2020, 40, 492-496.	1.1	11
44	Preference for secondary findings in prenatal and pediatric exome sequencing. Prenatal Diagnosis, 2022, 42, 753-761.	1.1	11
45	Women should decide which conditions matter. American Journal of Obstetrics and Gynecology, 2016, 215, 583-587.e1.	0.7	10
46	Expanded Carrier Screening. Obstetrics and Gynecology, 2017, 130, 260-261.	1.2	10
47	The utility of nuchal translucency ultrasound in identifying rare chromosomal abnormalities not detectable by cellâ€free DNA screening. Prenatal Diagnosis, 2020, 40, 185-190.	1.1	10
48	Society for Maternal-Fetal Medicine Consult Series #59: The use of analgesia and anesthesiaÂfor maternal-fetal procedures. American Journal of Obstetrics and Gynecology, 2021, 225, B2-B8.	0.7	10
49	Effects of Changes in Prenatal Aneuploidy Screening Policies in an Integrated Health Care System. Obstetrics and Gynecology, 2013, 121, 265-271.	1.2	9
50	Utility of chromosomal microarray in anomalous fetuses. Prenatal Diagnosis, 2018, 38, 140-147.	1.1	9
51	The Society for Maternal-Fetal Medicine (SMFM) Fetal Anomalies Consult Series. American Journal of Obstetrics and Gynecology, 2019, 221, B2-B24.	0.7	8
52	Pregnancy loss after amniocentesis in monochorionic and dichorionic twin pregnancies: Results from a large populationâ€based dataset. Prenatal Diagnosis, 2019, 39, 896-900.	1.1	8
53	Previous Adverse Outcome of Term Pregnancy and Risk of Preterm Birth in Subsequent Pregnancy. Maternal and Child Health Journal, 2019, 23, 443-450.	0.7	8
54	Genetic Counseling for Patients Considering Screening and Diagnosis for Chromosomal Abnormalities. Clinics in Laboratory Medicine, 2016, 36, 227-236.	0.7	7

#	Article	IF	Citations
55	Investigating human placentation and pregnancy using first trimester chorionic villi. Placenta, 2018, 65, 65-75.	0.7	7
56	Maternal genetic disorders and fetal development. Prenatal Diagnosis, 2020, 40, 1056-1065.	1.1	7
57	Society for Maternal-Fetal Medicine Consult SeriesÂ#55: Counseling women at increased riskÂof maternal morbidity and mortality. American Journal of Obstetrics and Gynecology, 2021, 224, B16-B23.	0.7	6
58	Genomic Sequencing Results Disclosure in Diverse and Medically Underserved Populations: Themes, Challenges, and Strategies from the CSER Consortium. Journal of Personalized Medicine, 2021, 11, 202.	1.1	6
59	Society for Maternal-Fetal Medicine Special Statement: Maternal-fetal medicine subspecialist survey on abortion training and service provision. American Journal of Obstetrics and Gynecology, 2021, 225, B2-B11.	0.7	6
60	Exome sequencing of fetuses with congenital diaphragmatic hernia supports a causal role for NR2F2, PTPN11, and WT1 variants. American Journal of Surgery, 2022, 223, 182-186.	0.9	6
61	Fetal Congenital Pulmonary Airway Malformation: The Role of an Objective Measurement of Cardiomediastinal Shift. American Journal of Perinatology, 2019, 36, 225-232.	0.6	5
62	Performance of noninvasive prenatal screening for 22q11.2 deletion syndrome in the SMART study. American Journal of Obstetrics and Gynecology, 2022, 227, 124-125.	0.7	5
63	COVID-19 Testing, Personal Protective Equipment, and Staffing Strategies Vary at Obstetrics Centers across the Country. American Journal of Perinatology, 2020, 37, 1482-1484.	0.6	4
64	Community Obstetrical Units Less Likely than Academic Units to Have Universal COVID-19 Testing. American Journal of Perinatology, 2020, 37, 1074-1076.	0.6	4
65	First-trimester combined screening: experience with an instant results approach. American Journal of Obstetrics and Gynecology, 2007, 196, 606.e1-606.e5.	0.7	3
66	Maternal and neonatal outcomes after antenatal corticosteroid administration for PPROM at 32 to 33 6/7 weeks gestational age. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 1676-1680.	0.7	3
67	Gender Differences in Academic Rank and NIH Funding among Academic Maternalâ€“Fetal Medicine Physicians in the United States. American Journal of Perinatology, 2019, 36, 443-448.	0.6	3
68	Twin chorionicity and zygosity both vary with maternal age. Prenatal Diagnosis, 2021, 41, 1074-1079.	1.1	3
69	Perinatal outcomes and 2017 ACC/AHA blood pressure categories. Pregnancy Hypertension, 2022, 28, 134-138.	0.6	3
70	Should cell-free DNA testing be used to target antenatal rhesus immune globulin administration?. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 1-5.	0.7	2
71	Optimizing use of existing prenatal genetic tests: Screening and diagnostic testing for aneuploidy. Seminars in Perinatology, 2018, 42, 296-302.	1.1	2
72	Primary cell-free DNA screening or contingent screening for the common trisomies: a response. American Journal of Obstetrics and Gynecology, 2022, 227, 127-128.	0.7	2

#	Article	IF	Citations
73	First-Trimester Screening for Chromosomal Abnormalities: Advantages of an Instant Results Approach. Clinics in Laboratory Medicine, 2010, 30, 565-571.	0.7	1
74	Obstetric Sonography: Why Are We Still Terrifying Pregnant Women?. Journal of Ultrasound in Medicine, 2018, 37, 2277-2278.	0.8	1
75	Response to â€œFurther genetic testing in prenatal cases of nonimmune hydrops fetalis with a normal array: a targeted panel or exome?â€• American Journal of Obstetrics and Gynecology, 2021, , .	0.7	1
76	Universal SARS-CoV-2 testing for obstetric inpatient units across the United States. Clinical Infectious Diseases, 2021, , .	2.9	1
77	Disparities in the acceptance of chromosomal microarray at the time of prenatal genetic diagnosis. Prenatal Diagnosis, 2022, , .	1.1	1
78	Reply. American Journal of Obstetrics and Gynecology, 2016, 215, 253-254.	0.7	0
79	The utility of pathologic examination and comprehensive phenotyping for accurate diagnosis with perinatal exome sequencing. Prenatal Diagnosis, 0, , .	1.1	0